IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1276-1291 out of 1291.

<< < 47 | 48 | 49 | 50 | 51 | 52

Public Release: 4-Nov-2015
Advanced Breast Cancer Third International Consensus Conference
Stop the damaging messages about advanced breast cancer and include us in your discussions
Organizations that issue 'damaging messages' about advanced breast cancer need to be identified and educated to change the way they talk about the disease, a patient will tell the Advanced Breast Cancer Third International Consensus Conference. In another presentation, a second patient will say that the voices of patients needed to be included in discussions between policy makers and the medical community about whether the high costs of second and third line treatments for the disease is financially sustainable by society.

Contact: Emma Mason
European School of Oncology

Public Release: 4-Nov-2015
International Journal of Gynecological Cancer
CK5 marks cisplatin-resistant ovarian cancer
A University of Colorado Cancer Center study recently published in the International Journal of Gynecological Cancer shows that protein cytokeratin 5 (CK5), known to be a marker of poor prognosis in breast cancer, also marks ovarian cancers likely to be resistant to the common chemotherapy cisplatin.
University of Colorado AMC Department of Obstetrics and Gynecology, National Institutes of Health

Contact: Garth Sundem
University of Colorado Anschutz Medical Campus

Public Release: 4-Nov-2015
170th Meeting of the Acoustical Society of America (ASA)
Sound waves levitate cells to detect stiffness changes that could signal disease
Utah Valley University physicists are literally applying rocket science to the field of medical diagnostics. With a few key changes, the researchers used a noninvasive ultrasonic technique originally developed to detect microscopic flaws in solid fuel rockets to successfully detect cell stiffness changes associated with certain cancers and other diseases. Brian Patchett will describe the group's method, which uses sound waves to manipulate and probe cells, during ASA's Fall 2015 Meeting.

Contact: John Arnst
Acoustical Society of America

Public Release: 4-Nov-2015
Nature Biotechnology
'JEDI' technology awakens new understanding of how immune system works
Scientists at Mount Sinai create immune cells that visibly kill cancer and pathogen infected cells

Contact: Sid Dinsay
The Mount Sinai Hospital / Mount Sinai School of Medicine

Public Release: 4-Nov-2015
Nature Communications
DNA in blood can track cancer development and response in real time
Scientists have shown for the first time that tumor DNA shed into the bloodstream can be used to track cancers in real time as they evolve and respond to treatment.
Cancer Research UK

Contact: Greg Jones
Cancer Research UK

Public Release: 4-Nov-2015
Science Translational Medicine
A way to target the Achilles heel of neuroblastoma
Australian scientists have identified a critical molecular 'feedback loop' that helps initiate and drive neuroblastoma, a cancer of the nervous system in children that is triggered in embryonal nerve cells. The research team have also identified an experimental drug, currently in clinical trials for adult cancer, with the potential to interrupt the loop and halt tumor progression.
National Health and Medical Research Council Australia, Cancer Institute NSW, Cancer Council NSW, Australian RotaryHealth/Rotary Club of Adelaide, Fund for Scientific Research Flanders, German Cancer Aid, German Ministry of Science and Education, others

Contact: Alison Heather
Children's Cancer Institute Australia

Public Release: 4-Nov-2015
Science Translational Medicine
Blood test picks out prostate cancer drug resistance
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment. The new research paves the way for information from a blood test to inform prostate cancer treatment in future, with only those patients whose cancers are free of resistance mutations taking the drug, abiraterone.
Cancer Research UK, Prostate Cancer UK, NIHR Biomedical Research Centre at the Royal Marsden and The Institute of Cancer Research, University of Trento

Contact: Claire Bithell
Institute of Cancer Research

Public Release: 4-Nov-2015
Journal of Clinical Oncology
Study rejects biologic age as limiting factor for stem cell transplants
More than 40 percent of older patients with acute myeloid leukemia (AML) can remain in long-term cancer remission through a modified, less aggressive approach to donor stem cell transplantation, according to the results of a phase 2 study led by oncologists at The Ohio State University Comprehensive Cancer Center -- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC -- James).
National Cancer Institute/Alliance for Clinical Trials in Oncology

Contact: Amanda Harper
Ohio State University Wexner Medical Center

Public Release: 4-Nov-2015
Mammography screening: Only 1 in 3 women is well-informed
Only one in three women participating in Germany's mammography screening program is well-informed about it: the higher the level of education, the greater the chance of women making an informed decision. These are the results of a study that health care researchers at Bielefeld University are publishing today in the international specialist journal PLOS ONE.

Contact: Dr. Jacob Spallek
Bielefeld University

Public Release: 3-Nov-2015
EMBO Journal
Uptake mechanisms of cytostatics discovered
Scientists at the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and the Leibniz-Institut für Molekulare Pharmakologie in Berlin, in cooperation with a Dutch group, have now succeeded in showing that the volume-regulated anion channel VRAC is 50 percent responsible for active substance uptake. The researchers have thus identified a potential cause for therapy resistance. The new findings have just appeared in the specialist magazine the EMBO Journal and hold high clinical relevance.

Contact: Josef Zens
Max Delbrück Center for Molecular Medicine in the Helmholtz Association

Public Release: 3-Nov-2015
Cancer-associated mutations are common in patients with unexplained low blood counts
Patients with unexplained low blood counts and abnormally mutated cells who do not fit the diagnostic criteria for recognized blood cancers should be described as having clonal cytopenias of undetermined significance (CCUS), suggest University of California, San Diego School of Medicine researchers in a recent paper published in the journal Blood. The researchers found the condition surprisingly common in older patients with low blood counts.
Genoptix Medical Laboratory, National Institute of Diabetes and Digestive and Kidney Diseases

Contact: Yadira Galindo
University of California - San Diego

Public Release: 3-Nov-2015
Stem Cell Reports
Blood stem cell self-renewal dependent on surroundings
Stem cells have two important capabilities: they can develop into a wide range of cell types and simultaneously renew themselves, creating fresh stem cells. Using a model of the blood forming (hematopoietic) system, researchers at the Technical University of Munich have now been able to precisely determine, which signaling pathways play an essential role in the self-renewal of blood stem cells. A particularly decisive role in this process is the interactive communication with surrounding tissue cells in the bone marrow.

Contact: Vera Siegler
Technical University of Munich (TUM)

Public Release: 3-Nov-2015
Western Surgical Association Annual Meeting
Study: Only 1 in 5 US pancreatic cancer patients get this key blood test at diagnosis
Only one in five US pancreatic cancer patients receive a widely available, inexpensive blood test at diagnosis that can help predict whether they are likely to have a better or worse outcome than average and guide treatment accordingly, a Mayo Clinic study shows.
Mayo Clinic

Contact: Sharon Theimer
Mayo Clinic

Public Release: 3-Nov-2015
Pediatric Blood and Cancer
Chemotherapy-induced hearing loss affects cognition in pediatric brain tumor survivors
More children are surviving malignant brain tumors than in the past, thanks to the use of intense treatments using platinum-based chemotherapy (cisplatin and high-dose carboplatin). Unfortunately, the therapy has a known side effect of permanent hearing loss, resulting from damage to the inner ear. Investigators at Children's Hospital Los Angeles now report that this type of chemotherapy may not only impact hearing, but that the hearing loss may then contribute to long-term neurocognitive deficits.
National Institutes of Health

Contact: Ellin Kavanagh
Children's Hospital Los Angeles

Public Release: 3-Nov-2015
Human Pathology
Simple test predicts response to chemotherapy in lung cancer patients
Scientists at Lawson Health Research Institute have found that adenocarcinoma patients who undergo chemotherapy and surgery experience significantly improved survival rates when their tumor is lacking the retinoblastoma tumor suppressor protein. This new information is very useful as it may predict which patients will respond best to chemotherapy.

Contact: Robert DeLaet
519-685-8500 x75664
Lawson Health Research Institute

Public Release: 3-Nov-2015
Mayo Clinic Proceedings
Standing and exercise linked to lower odds of obesity
Standing for at least one-quarter of the day has been linked to lower odds of obesity in a new study.

Contact: David Sampson
American Cancer Society

Showing releases 1276-1291 out of 1291.

<< < 47 | 48 | 49 | 50 | 51 | 52

  Search News Releases